Compare NYAX & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NYAX | MLYS |
|---|---|---|
| Founded | 2005 | 2019 |
| Country | Israel | United States |
| Employees | 1200 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.4B |
| IPO Year | 2022 | 2023 |
| Metric | NYAX | MLYS |
|---|---|---|
| Price | $60.85 | $23.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $49.50 | $48.67 |
| AVG Volume (30 Days) | 15.4K | ★ 1.1M |
| Earning Date | 03-09-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $25.96 | N/A |
| Revenue Next Year | $19.69 | N/A |
| P/E Ratio | $89.78 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $32.38 | $10.44 |
| 52 Week High | $61.50 | $47.65 |
| Indicator | NYAX | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 62.08 | 30.24 |
| Support Level | $42.63 | $13.42 |
| Resistance Level | $60.77 | $31.09 |
| Average True Range (ATR) | 1.17 | 1.76 |
| MACD | 0.48 | -0.30 |
| Stochastic Oscillator | 88.47 | 11.34 |
Nayax Ltd is an end-to-end retail technology platform for unattended commerce. It unifies payments, operations management, and customer engagement tools into a powerful, adaptable platform for modern commerce. It provides solutions that empower businesses to enhance customer experience, accept cashless payments, and manage their operations with a robust Internet of Things (IoT) software platform, helping achieve long-term growth. The company addresses a broad range of retail verticals, including all types of vending machines, coffee machines, unattended checkout counters, self-service kiosks, ticketing machines, car wash stations, gaming machines, amusement rides, laundromats, EV charging stations, and many more.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.